Published Online:https://doi.org/10.5465/amp.2019.0023

The extent and impact of neglected diseases has been well documented in the public health and medical science literature. However, from a strategic management and organizational perspective, there is a gap in understanding the complex relationships that underpin the functioning of product development partnerships (PDPs) in managing the drug development process. This paper focuses on (a) identifying the importance of PDPs in the development of new drugs for neglected and emerging infectious diseases and (b) identifying the key stakeholders and their relationships and (levels of) dependencies in PDPs through the resource dependence lens. Our model offers a unique perspective to the strategic alliance literature not only by showing the complex interrelationships among various stakeholders but also in highlighting power, trust, and governance as key challenges. Based on our extensive analysis of the literature and the contextualization of the recent novel coronavirus epidemic as a case, we offer conclusions and reflections from a management perspective on the ability of PDPs to mitigate risks related to neglected and emerging infectious diseases.

References

  • Aerts, C., Sunyoto, T., Tediosi, F., & Sicuri, E. (2017). Are public-private partnerships the solution to tackle neglected tropical diseases? A systematic review of the literature. Health Policy (Amsterdam), 121, 745–754. Google Scholar
  • Boulton, I., Meredith, S., Mertenskoetter, T., & Glaue, F. (2015). Evaluation of the product development partnerships (PDP) funding activities. London: Foreign, Commonwealth & Development Office. Retrieved from https://www.gov.uk/research-for-development-outputs/evaluation-of-the-product-development-partnerships-pdp-funding-activities-200715 Google Scholar
  • Brooks, A. D., et al.. (2010). Ensuring that developing countries have access to new healthcare products: The role of product development partnerships. Innovation Strategy Today, 3, 1–5. Google Scholar
  • BVGH & BIO. (2012). Biotechnology: Bringing innovation to neglected disease research and development. A joint report by BIO Ventures for Global Health (BVGH) and the Biotechnology Industry Organization (BIO). Retrieved from https://archive.bio.org/sites/default/files/FINAL%20Biotech%20report.pdf Google Scholar
  • Buse, K., & Waxman, A. (2001). Public-private health partnerships: A strategy for WHO. Bulletin of the World Health Organization, 79, 748–754. Google Scholar
  • Casciaro, T., & Piskorski, M. J. (2005). Power imbalance, mutual dependence, and constraint absorption: A closer look at resource dependence theory. Administrative Science Quarterly, 50, 167–199. Google Scholar
  • Chataway, J., Brusoni, S., Cacciatori, E., Hanlin, R., & Orsenigo, L. (2007). The International AIDS Vaccine Initiative (IAVI) in a changing landscape of vaccine development: A public–private partnership as knowledge broker and integrator. European Journal of Development Research, 19, 100–117. Google Scholar
  • Craft, J. C. (2008). Challenges facing drug development for malaria. Current Opinion in Microbiology, 11, 428–433. Google Scholar
  • Dare, L. (2003). WHO and the challenges of the next decade. Lancet, 361(9352), 170–171. Google Scholar
  • Das, T. K., & Teng, B. S. (1998). Between trust and control: Developing confidence in partner cooperation in alliances. Academy of Management Review, 23(3), 491–512.LinkGoogle Scholar
  • de Vrueh, R. L., & Crommelin, D. J. (2017). Reflections on the future of pharmaceutical public-private partnerships: from input to impact. Pharmaceutical Research, 34, 1985–1999. Google Scholar
  • Fink, R. C., Edelman, L. F., Hatten, K. J., & James, W. L. (2006). Transaction cost economics, resource dependence theory, and customer–supplier relationships. Industrial and Corporate Change, 15(3), 497–529. Google Scholar
  • Gargiulo, M. (1993). Two-step leverage: Managing constraint in organizational politics. Administrative Science Quarterly, 38, 1–19. Google Scholar
  • G-Finder Report. (2018). Neglected disease research and development: Reaching new heights. Sydney, Australia: G-Finder. Retrieved from https://gfinderdata.policycuresresearch.org/pages/data-visualisations/allNeglectedDiseases Google Scholar
  • Global Risks Report. (2018). Global risks 2018 (13th ed.). Geneva: World Economic Forum, Retrieved from http://www3.weforum.org/docs/WEF_GRR18_Report.pdf Google Scholar
  • Goldberg, D. E., Siliciano, R. F., & Jacobs, W. R., Jr. (2012). Outwitting evolution: Fighting drug-resistant TB, malaria, and HIV. Cell, 148(6), 1271–1283. Google Scholar
  • Grace, C., & Britain, G. (2010). Product development partnerships (PDPs): Lessons from PDPs established to develop new health technologies for neglected diseases. London, UK: Department for International Development, Human Development Resource Centre. Google Scholar
  • Gulati, R., & Sytch, M. (2008). Does familiarity breed trust? Revisiting the antecedents of trust. Managerial and Decision Economics, 29, 165–190. Google Scholar
  • Gulati, R., Wohlgezogen, F., & Zhelyazkov, P. (2012). The two facets of collaboration: Cooperation and coordination in strategic alliances. Academy of Management Annals, 6(1), 531–583.LinkGoogle Scholar
  • Gustavsen, K., & Hanson, C. (2009). Progress in public-private partnerships to fight neglected diseases. Health Affairs, 28, 1745–1749. Google Scholar
  • Handfield, R. B. (1993). A resource dependence perspective of just-in-time purchasing. Journal of Operations Management, 11, 289–311. Google Scholar
  • Hillman, A. J., Withers, M. C., & Collins, B. J. (2009). Resource dependence theory: A review. Journal of Management, 35, 1404–1427. Google Scholar
  • Howells, J., Gagliardi, D., & Malik, K. (2008). The growth and management of R&D outsourcing: Evidence from UK pharmaceuticals. R & D Management, 38, 205–219. Google Scholar
  • Hsueh, P. R., Chen, W. H., & Luh, K. T. (2005). Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991–2003 at a university hospital in Taiwan. International Journal of Antimicrobial Agents, 26, 463–472. Google Scholar
  • IDRC. (2013). The value-for-money discourse: Risks and opportunities for R4D. Ontario, Canada: Author. Retrieved from http://www.idrc.ca/EN/Documents/Value-for-Money-Partnership-Practices-3.pdf Google Scholar
  • Kim, Y., & Cannella, A. A. (2008). Toward a social capital theory of director selection. Corporate Governance, 16(4), 282–293. Google Scholar
  • Lang, T., & Greenwood, B. (2003). The development of Lapdap, an affordable new treatment for malaria. Lancet Infectious Diseases, 3, 162–168. Google Scholar
  • Lezaun, J., & Montgomery, C. M. (2015). The pharmaceutical commons: Sharing and exclusion in global health drug development. Science, Technology & Human Values, 40, 3–29. Google Scholar
  • Looney, W. (2011). The power of product development partnerships. Pharmaceutical Executive. Retrieved from http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=739264 Google Scholar
  • Lowman, M., Trott, P., Hoecht, A., & Sellam, Z. (2012). Innovation risks of outsourcing inpharmaceutical new product development. Technovation, 32(2), 99–109. Google Scholar
  • Lumineau, F., & Quélin, B. V. (2012). An empirical investigation of interorganizational opportunism and contracting mechanisms. Strategic Organization, 10(1), 55–84. Google Scholar
  • Lynall, M. D., Golden, B. R., & Hillman, A. J. (2003). Board composition from adolescence to maturity: A multitheoretic view. Academy of Management Review, 28(3), 416–431.LinkGoogle Scholar
  • Mahmoud, A., Danzon, P. M., Barton, J. H., & Mugerwa, R. D. (2006). Product development priorities. Disease Control Priorities in Developing Countries, 139–156. Google Scholar
  • Mohiuddin, M., Nurul, M., Mazumder, H., Chrysostome, E., & Su, Z. (2017). Relocating high-tech industries to emerging markets: The case of pharmaceutical industry outsourcing to India. Transnational Corporations Review, 9(3), 201–217. Google Scholar
  • Moran, M. (2005). A breakthrough in R&D for neglected diseases: New ways to get the drugs we need. PLoS Medicine, 2, e302. Google Scholar
  • Moran, M., Guzman, J., Ropars, A.-L., & Illmer, A. (2010). The role of product development partnerships in research and development for neglected diseases. International Health, 2(2), 114–122. Google Scholar
  • Moran, M., Guzman, J., Ropars, A.-L., McDonald, A., Jameson, N., & Omune, B. (2009). Neglected disease research and development: How much are we really spending? PLoS Medicine, 6(2), e1000030. Google Scholar
  • Moran, M., & Stevenson, M. (2013). Illumination and innovation: What philanthropic foundations bring to global health governance. Global Society, 27, 117–137. Google Scholar
  • Moran, M., et al.. (2014). Neglected disease research & development: Emerging trends. Sydney, Australia: The George Institute for Global Health, Health Policy Division. Google Scholar
  • Muñoz, V., Visentin, F., Foray, D., & Gaulé, P. (2015). Can medical products be developed on a non-profit basis? Exploring product development partnerships for neglected diseases. Science & Public Policy, 42, 315–338. Google Scholar
  • Nambiar, S., Laessig, K., Toerner, J., Farley, J., & Cox, E. (2014). Antibacterial drug development: Challenges, recent developments, and future considerations. Clinical Pharmacology and Therapeutics, 96, 147–149. Google Scholar
  • Narula, R., & Hagedoorn, J. (1999). Innovating through strategic alliances: Moving towards international partnerships and contractual agreements. Technovation, 19(5), 283–294. Google Scholar
  • Nisar, M. A., & Hayter, C.S. (2018). Product development partnerships: Collaborative multi-sector regimes to accelerate vaccine development. In A. Farazmand (Ed.), Global encyclopedia of public administration, public policy, and governance. Cham, Switzerland: Springer. Google Scholar
  • Nwaka, S., & Ridley, R. G. (2003). Science & society: Virtual drug discovery and development for neglected diseases through public–private partnerships. Nature Reviews. Drug Discovery, 2(11), 919–928. Google Scholar
  • Panda, S., et al.. (2017). Drug resistance in malaria, tuberculosis, and HIV in South East Asia: Biology, programme, and policy considerations. British Medical Journal, 358, j3545. Google Scholar
  • Papaioannou, T., Wield, D., & Chataway, J. (2009). Knowledge ecologies and ecosystems? An empirically grounded reflection on recent developments in innovation systems theory. Environment and Planning. C, Government & Policy, 27, 319–339. Google Scholar
  • Patnaik, S. (2011). Inter-organisational collaborations as embedded social systems: A critical realist explanation of alliance evolution. Unpublished doctoral thesis, University of Liverpool, Liverpool, England. Google Scholar
  • Pedrique, B., et al.. (2013). The drug and vaccine landscape for neglected diseases (2000–11): A systematic assessment. Lancet. Global Health, 1, 371–379. Google Scholar
  • Pfeffer, J., & Salancik, G. (1978). The external control of organizations: A resource dependence perspective. New York: Harper & Row. Google Scholar
  • Pratt, B., & Loff, B. (2012). Contribution of product development partnerships to access to medicines and research capacity strengthening. Lancet, 380(2), 1968–1978. Google Scholar
  • Ridley, R. G. (2001). Putting the partnership into public-private partnerships. Bulletin of the World Health Organization 79, 694. Google Scholar
  • Roijakkers, N., & Hagedoorn, J. (2006). Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: Trends, patterns, and networks. Research Policy, 35, 431–446. Google Scholar
  • Rousseau, D. M., Sitkin, S. B., Burt, R. S., & Camerer, C. (1998). Not so different after all: A cross-discipline view of trust. Academy of Management Review, 23(3), 393–404.LinkGoogle Scholar
  • Schuhmacher, A., Gassmann, O., & Hinder, M. (2016). Changing R&D models in research-based pharmaceutical companies. Journal of Translational Medicine, 14(105), 1–11. Google Scholar
  • Silver, L. L. (2011). Challenges of antibacterial discovery. Clinical Microbiology Reviews, 24, 71–109. Google Scholar
  • Trouiller, P., Olliaro, P., Torreele, E., Orbinski, J., Laing, R., & Ford, N. (2002). Drug development for neglected diseases: A deficient market and a public-health policy failure. Lancet, 359(9324), 2188–2194. Google Scholar
  • Varda, D., Shoup, J. A., & Miller, S. (2012). A systematic review of collaboration and network research in the public affairs literature: Implications for public health practice and research. American Journal of Public Health, 102, 564–571. Google Scholar
  • Vecchi, V.Hellowell, M. (Eds.). (2018). Public-private partnerships in health: Improving infrastructure and technology. London: Palgrave Macmillon. Google Scholar
  • Watts, G. (2016). Drug development partnerships look set to grow. Lancet, 388(10039), 16–18. Google Scholar
  • Widdus, R. (2001). Public-private partnerships for health: Their main targets, their diversity, and their future directions. Bulletin of the World Health Organization, 79, 713–720. Google Scholar
  • World Health Organization. (2006). Public health-innovation and intellectual property rights: Report of the commission on intellectual property rights, innovation and public health. Geneva: Author. Google Scholar
  • World Health Organization. (2015). Trade, foreign policy, diplomacy and health: Public–private partnerships for health. Geneva: Author. Google Scholar
  • World Health Organization. (2018). Antimicrobial resistance. Geneva: Author. Retrieved from https://www.who.int/antimicrobial-resistance/en/ Google Scholar
  • Yang, P., Chen, Y., Jiang, S., Shen, P., Lu, X., & Xiao, Y. (2018). Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014. Antimicrobial Resistance and Infection Control, 7, 137. Google Scholar
  • Zaheer, A., & Harris, J. (2006). Interorganizational Trust. In O. ShenkarJ. J. Reuer (Eds.), Handbook of strategic alliances (pp. 169–197). Thousand Oaks, CA: Sage. Google Scholar
  • Zahra, S. A., Filatotchev, I., & Wright, M. (2009). How do threshold firms sustain corporate entrepreneurship? The role of boards and absorptive capacity. Journal of Business Venturing, 24(3), 248–260. Google Scholar
  • Zorzet, A. (2014). Overcoming scientific and structural bottlenecks in antibacterial discovery and development. Upsala Journal of Medical Sciences, 119, 170–175. Google Scholar
Academy of Management
  Academy of Management
  100 Summit Lake Drive, Suite 110
  Valhalla, NY 10595, USA
  Phone: +1 (914) 326-1800
  Fax: +1 (914) 326-1900